Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.